PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17121918-9	2006	Combined treatment with 10 micromol/L celecoxib and MK886 could prevent this activation and had additive effects on inhibiting tumor cell proliferation, inducing cell apoptosis, decreasing Bcl-2 expression, increasing Bax expression, and determining mitochondrial depolarization in comparison with treatment with either inhibitor alone.	MK-886	52-57	BCL2 associated X, apoptosis regulator	Homo sapiens	218-221	
20061081-7	2010	MK886 (5-LOX activating protein inhibitor) mediated the induction of apoptosis by elevation of caspase-3 and Bax/Bcl2 ratio.	MK-886	0-5	BCL2 associated X, apoptosis regulator	Homo sapiens	109-112	
14675240-0	2004	Five-lipoxygenase-activating protein inhibitor MK-886 induces apoptosis in gastric cancer through upregulation of p27kip1 and bax.	MK-886	47-53	BCL2 associated X, apoptosis regulator	Homo sapiens	126-129	
14675240-11	2004	CONCLUSION: The present results suggest that MK-886 induces apoptosis in gastric cancer cells through upregulation of p27kip1 and bax, and that MK-886 is a potentially useful drug in gastric cancer prevention and therapy.	MK-886	45-51	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133	
14675240-11	2004	CONCLUSION: The present results suggest that MK-886 induces apoptosis in gastric cancer cells through upregulation of p27kip1 and bax, and that MK-886 is a potentially useful drug in gastric cancer prevention and therapy.	MK-886	144-150	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133